Figure 2 Profile of sorbitol fermentation by P. acidipropionici for the second sequential batch operating in four independent vessels simultaneously.
In particular, in the constant volume ignition case, reactions present in the third sequential O2 addition reaction pathways (e.g., KDHP → products + OH) contribute significantly to the explosivity of the mixture; when accounted for along with reactions P OOH 2 + O2 → OOP OOH 2 and OOP OOH 2 → KDHP + OH, they decrease ignition delay time of the mixture by up to 40%.
In the present study, the average propionic acid/acetic acid (P/A) molar ratio was increased from 9.7 in the first batch to 13.8 in the third sequential batch when using sorbitol as a carbon source.
In the ninth sequential pattern, we can observe among the young researches that published papers at EASE (28%%), all of them (100%%) published a paper at SBES in the future (as shown in the confidence column).
Hardly any further weight loss in the TG curve can be observed at temperatures above 330 °C, indicating the completion of reaction as shown in the third sequential weight loss.
As expected, the propionic acid/succinic acid (P/S) molar ratio decreased from 10.3 in the first batch to 3.7 in the third sequential batch, once the concentration of succinic acid increased from 6.1 ± 2.1 to 14.8 ± 0.9 g L−1 and that of propionic acid decreased from 39.5 ± 5.2 to 34.4 ± 1.9 g L−1 (Table 6).
Blanc and Goma (1987) obtained a productivity of 0.10 g L−1 h−1 for acetic acid while in the present work, the productivity of acetic acid decreased from 0.05 g L−1 h−1 in the first batch to 0.03 g L−1 h−1 in the third sequential batch (Table 4).
On the other hand, in the abstract test, both the males and the females showed no significant difference in the third sequential RT obtained for the abstract test versus the baseline training trials.
In the first sequential (SEQ) protocol, 2 three-weekly courses of neoadjuvant chemotherapy were applied, consisting of cisplatin (CDDP; 100 mg/m2 i.v., on day 1) followed by 50 mg/m2 folinic acid (day 1) and parallel 120 h continuous infusions of folinic acid (250 mg/m2 per day, days 1 5) and 5-fluorouracil (600 mg/m, days 1 5).
